Chemotherapy News and Research

Latest Chemotherapy News and Research

WHO spokesperson addresses health, medical needs for Libya on PBS NewsHour

The WHO "is rushing to secure medical supplies for Libya" after the Dutch government on Monday released nearly $145 million in frozen assets from Libyan leader Moammar Qaddafi's regime in response to a direct WHO appeal, PBS NewsHour reports.

20 Aug 2011

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration has granted accelerated approval of ADCETRISTM for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.

20 Aug 2011

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

The U.S. Food and Drug Administration today approved Adcetris to treat Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large cell lymphoma.

20 Aug 2011

Temple University, URMC partner to translate novel medical research into new drugs

The University of Rochester Medical Center (URMC) and Temple University School of Pharmacy have announced a partnership that will help translate novel medical research into new drugs for treating diseases.

19 Aug 2011

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

DARA BioSciences, Inc. announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer.

19 Aug 2011

EMA accepts Merck and ARIAD's MAA for ridaforolimus to treat metastatic bone sarcomas

Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has completed its administrative validation process for the regulatory application for ridaforolimus, an investigational oral mTOR inhibitor developed for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy.

18 Aug 2011

New leukemia drug in early clinical testing offers some clues for better treatment

While testing a new drug designed to treat chronic leukemia, researchers at Cleveland Clinic discovered new markers that could identify which patients would receive maximum benefit from the treatment.

18 Aug 2011

Herbal supplements may weaken the effect of chemotherapy drugs

Acai berry, cumin, herbal tea, turmeric and long-term use of garlic - all herbal supplements commonly believed to be beneficial to your health - may negatively impact chemotherapy treatment according to a new report presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago this summer.

18 Aug 2011

New process may eliminate need for full genome sequencing for cancer patients

People at risk for a certain form of colon and other types of cancer may soon have a better chance at surviving or even avoiding the diseases, thanks to a new study done by the Intermountain Clinical Genetics Institute at LDS Hospital.

18 Aug 2011

FDA approves Zelboraf (vemurafenib) for advanced skin cancer

A new drug was approved for advanced skin cancer this Wednesday by U.S. regulators, offering the first new treatment for melanoma in 13 years.

18 Aug 2011

FDA approves Mayo Clinic's ovarian and breast cancer vaccines

Mayo Clinic has received investigational new drug approval from the Food and Drug Administration for two new cancer vaccines that mobilize the body's defense mechanisms to destroy malignant cells.

18 Aug 2011

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.

18 Aug 2011

CEL-SCI receives Chinese patent for Multikine cancer drug

CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.

18 Aug 2011

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

18 Aug 2011

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Allos Therapeutics, Inc. today announced the enrollment of the first patient in a Phase 3 randomized clinical trial (PDX-017) evaluating FOLOTYN in patients with previously undiagnosed peripheral T-cell lymphoma.

18 Aug 2011

Roche receives FDA approval for Zelboraf to treat BRAF mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test.

18 Aug 2011

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Emergent BioSolutions Inc. today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin's B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma.

17 Aug 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

WHO spokesperson addresses health, medical needs for Libya on PBS NewsHour

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

Temple University, URMC partner to translate novel medical research into new drugs

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

EMA accepts Merck and ARIAD's MAA for ridaforolimus to treat metastatic bone sarcomas

New leukemia drug in early clinical testing offers some clues for better treatment

Herbal supplements may weaken the effect of chemotherapy drugs

New process may eliminate need for full genome sequencing for cancer patients

FDA approves Zelboraf (vemurafenib) for advanced skin cancer

FDA approves Mayo Clinic's ovarian and breast cancer vaccines

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

CEL-SCI receives Chinese patent for Multikine cancer drug

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Roche receives FDA approval for Zelboraf to treat BRAF mutation-positive metastatic melanoma

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Clinical trial to assess 6MP drug in women with advanced breast or ovarian cancer

Drug SLM3 prevents multiplication of tumor cells

Patrys product shows activity in multiple myeloma cancer cells

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in